Statin Therapy in Venous Thromboembolism: How Far from Primary and Secondary Prevention?
Rong Jiang,Zhi‐Cheng Jing
DOI: https://doi.org/10.1111/jth.15752
2022-01-01
Journal of Thrombosis and Haemostasis
Abstract:Statin therapy is highly recommended for the primary and secondary prevention of arterial thrombosis diseases, including coronary and cerebral atherosclerosis.1.Safouris A. Krogias C. Sharma V.K. et al.Statin pretreatment and microembolic signals in large artery atherosclerosis.Arterioscler Thromb Vasc Biol. 2017; 37: 1415-142210.1161/ATVBAHA.117.309292Crossref PubMed Scopus (26) Google Scholar Several studies also indicate the beneficial effect of statins on venous thrombus, namely venous thromboembolism (VTE) and pulmonary embolism (PE), regardless of healthy people or patients.2.Ashrani A.A. Barsoum M.K. Crusan D.J. Petterson T.M. Bailey K.R. Heit J.A. Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population‐based case‐control study.Thromb Res. 2015; 135: 1110-111610.1016/j.thromres.2015.04.005Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar, 3.Glynn R.J. Danielson E. Fonseca F.A. et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N Engl J Med. 2009; 360: 1851-186110.1056/NEJMoa0900241Crossref PubMed Scopus (605) Google Scholar, 4.Braekkan S.K. Caram‐Deelder C. Siegerink B. et al.Statin use and risk of recurrent venous thrombosis: results from the MEGA follow‐up study.Res Pract Thromb Haemost. 2017; 1: 112-11910.1002/rth2.12003Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar, 5.Smith N.L. Harrington L.B. Blondon M. et al.The association of statin therapy with the risk of recurrent venous thrombosis.J Thromb Haemost. 2016; 14: 1384-139210.1111/jth.13334Crossref PubMed Scopus (25) Google Scholar A randomized trial demonstrated rosuvastatin significantly reduced the incidence of VTE, beyond its influence on arterial thrombosis.3.Glynn R.J. Danielson E. Fonseca F.A. et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N Engl J Med. 2009; 360: 1851-186110.1056/NEJMoa0900241Crossref PubMed Scopus (605) Google Scholar In addition, statins may moderately lower the risk of recurrent VTE among patients with a provoked first VTE (hazard ratio: 0.64, 95% confidence interval (CI): 0.27–1.58). However, so far there is little evidence showing that statin therapy can reduce the risk of fatal PE. Therefore, Can the reduced recurrence risk of VTE caused by statin bring more benefit for reduced the risk of death of acute PE? Siniscalchi et al. have addressed this interesting question and reported statin use is associated with a lower short‐term mortality in patients with acute symptomatic PE.6.Siniscalchi C. Quintavalla R. Rocci A. et al.Statin and all‐cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry.Eur J Intern Med. 2019; 68: 30-3510.1016/j.ejim.2019.07.028Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar They used the Registro Informatizado de Pacientes con Enfermedad TromboEmbólica (RIETE) registry, a large multicenter, ongoing, international registry of patients with objectively confirmed, acute VTE (ClinicalTrials.gov identifier: NCT02832245), to assess the correlation between statin therapy and short‐term mortality. Among 31 169 patients with acute symptomatic PE enrolled between 2009 and 2021, 5520 (18%) were using statins: 829 at low intensity, 3636 at intermediate intensity, and 1055 at high intensity. Compared to non‐users, statin users were 10 years older and prone to have hypertension, diabetes, chronic heart or renal failure, prior myocardial infarction, prior stroke, or peripheral artery disease. They were also more likely to use antiplatelet drugs and had lower serum levels of low density lipoprotein (LDL) cholesterol than non‐users. Despite similar proportion of initial PE and hypotension, statin users were more likely to have hypoxemia, raised troponin levels, and worse scored PE severity score than non‐users. Compared to non‐users, statin users had similar anticoagulant therapy; the odd ratios (ORs) of all‐cause death and fatal PE among statin users were 0.65 (95% CI: 0.56–0.76) and 0.42 (95% CI: 0.28–0.62) after multiple adjustment, respectively, which suggests statin use exerts beneficial effects on short‐term mortality of acute PE. The mortality rate was lower than those of another two studies, which also used the data from the RIETE registry and found statin users at baseline had a significant decreased 177‐ or 192‐day all‐cause mortality compared to non‐statin users (4.7%, 9.9%, 8.3%, respectively).6.Siniscalchi C. Quintavalla R. Rocci A. et al.Statin and all‐cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry.Eur J Intern Med. 2019; 68: 30-3510.1016/j.ejim.2019.07.028Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar, 7.Siniscalchi C. Surinach J.M. Visona A. et al.Different types of statins and all‐cause mortality during anticoagulation for venous thromboembolism: validation study from RIETE Registry.TH Open. 2020; 4: e236-e24410.1055/s‐0040‐1716734Crossref Google Scholar This study indicates a protective effect of statin in outcomes of PE. Interestingly, the authors also compare the effect of three different statin intensities and show an obvious benefit of all three intensities on the all‐cause death compared to the non‐users, while patients using low‐ or moderate‐intensity statins were at a lower risk of fatal PE, compared to those using high‐intensity statins and non‐users. Why would statins affect the short‐term mortality of acute PE? Statins can act through several mechanisms to repress the occurrence of VTE. On the one hand, statins lower LDL cholesterol, and reduce the risk factors for hyperlipidemia in VTE. The lower effect may be due to a healthier lifestyle and/or a lower risk condition in people receiving statins. Statins are known to reduce mortality, especially cardiovascular death, in patients with a history of cardiovascular disease (CVD).8.Biere‐Rafi S. Hutten B.A. Squizzato A. et al.Statin treatment and the risk of recurrent pulmonary embolism.Eur Heart J. 2013; 34: 1800-180610.1093/eurheartj/eht046Crossref PubMed Scopus (70) Google Scholar However, some studies have suggested that lipids are not associated with recurrence in patients with unprovoked first events.9.Morelli V.M. Lijfering W.M. Rosendaal F.R. Cannegieter S.C. Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow‐up study.J Thromb Haemost. 2017; 15: 695-70110.1111/jth.13640Crossref Scopus (9) Google Scholar The lower effect was consistent both in the presence or absence of VTE‐related clinical risk factors, such as hyperlipidemia.10.Cheung K.L. Zakai N.A. Callas P.W. et al.Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study.J Thromb Haemost. 2018; 16: 1743-175210.1111/jth.14235Crossref Scopus (13) Google Scholar, 11.Joseph P. Glynn R. Lonn E. et al.Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE‐3 and JUPITER randomized controlled trials.Cardiovasc Res. 2022; 118: 897-90310.1093/cvr/cvab078Crossref PubMed Scopus (7) Google Scholar On the other hand, statins can affect the blood coagulation system to reduce risk of VTE. They can reduce tissue factor expression and thrombin generation, attenuate fibrinogen cleavage, and increase the activity of the transcription factor Kruppel‐like factor 2, thereby promoting thrombomodulin expression on endothelial cells, which enhances the activity of the protein C anticoagulant pathway.12.Sen‐Banerjee S. Mir S. Lin Z. et al.Kruppel‐like factor 2 as a novel mediator of statin effects in endothelial cells.Circulation. 2005; 112: 720-72610.1161/CIRCULATIONAHA.104.525774Crossref PubMed Scopus (260) Google Scholar Ramberg et al.13.Ramberg C. Hindberg K. Biedermann J.S. et al.Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: a randomized controlled trial.J Thromb Haemost. 2022; 20: 877-88710.1111/jth.15626Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar demonstrated that statin treatment caused a substantial decreased activity of plasma procoagulant phospholipids (PPL), and then attenuated a PPL‐dependent coagulation activation, which may also contribute to a reduced VTE risk following statin treatment. The Siniscalchi et al. study is a registration observational study with no randomization to statin versus non‐statin users. Thus, some non‐measured variables, such as the reason for receiving statins, or patient preference or socioeconomical factors impacting the use of statins, have not been considered. Assuming that statins are effective in short‐term mortality of acute PE, three basic questions should be solved:•First, when should patients or healthy persons initiate statin use? What kind of people may benefit? Should statins be used in primary or secondary prevention of VTE?•Second, of the different statins, which is more efficient?•Third, what intensity should be taken? Considering the common side effects related to statin therapy impacting compliance are liver function injury and statin‐associated muscle systems. It is known to all that statin therapy is recommended for primary and secondary prevention of CVD and is cost effective.14.Kohli‐Lynch C.N. Lewsey J. Boyd K.A. et al.Beyond ten‐year risk: a cost‐effectiveness analysis of statins for the primary prevention of cardiovascular disease.Circulation. 2022; 145: 1312-132310.1161/CIRCULATIONAHA.121.057631Crossref Scopus (4) Google Scholar Nevertheless, statin utility in the primary prevention of VTE will be low, because the small absolute benefit of statin treatment may be counteracted by side effects, such as liver function injury, rhabdomyolysis, or incident diabetes.15.Sattar N. Preiss D. Murray H.M. et al.Statins and risk of incident diabetes: a collaborative meta‐analysis of randomised statin trials.Lancet. 2010; 375: 735-74210.1016/S0140‐6736(09)61965‐6Abstract Full Text Full Text PDF PubMed Scopus (1885) Google Scholar Nonetheless, statins seem not to have an effect on recurrence in patients with an unprovoked first event.4.Braekkan S.K. Caram‐Deelder C. Siegerink B. et al.Statin use and risk of recurrent venous thrombosis: results from the MEGA follow‐up study.Res Pract Thromb Haemost. 2017; 1: 112-11910.1002/rth2.12003Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar On one hand, there is opposite evidence of the association of VTE with levels of high‐density lipoprotein, LDL, or total cholesterol,3.Glynn R.J. Danielson E. Fonseca F.A. et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N Engl J Med. 2009; 360: 1851-186110.1056/NEJMoa0900241Crossref PubMed Scopus (605) Google Scholar, 16.Eichinger S. Pecheniuk N.M. Hron G. et al.High‐density lipoprotein and the risk of recurrent venous thromboembolism.Circulation. 2007; 115: 1609-161410.1161/CIRCULATIONAHA.106.649954Crossref PubMed Scopus (90) Google Scholar but on the other hand, although rosuvastatin significantly reduced the incidence of symptomatic VTE in a randomized trial in apparently healthy individuals, the recommendation of statins for primary prevention still needs to be confirmed by more high‐quality studies.3.Glynn R.J. Danielson E. Fonseca F.A. et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N Engl J Med. 2009; 360: 1851-186110.1056/NEJMoa0900241Crossref PubMed Scopus (605) Google Scholar Statin therapy can reduce the risk of recurrent VTE and mortality. In addition, statin therapy can help to reduce all‐cause mortality and CVD.6.Siniscalchi C. Quintavalla R. Rocci A. et al.Statin and all‐cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry.Eur J Intern Med. 2019; 68: 30-3510.1016/j.ejim.2019.07.028Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar, 7.Siniscalchi C. Surinach J.M. Visona A. et al.Different types of statins and all‐cause mortality during anticoagulation for venous thromboembolism: validation study from RIETE Registry.TH Open. 2020; 4: e236-e24410.1055/s‐0040‐1716734Crossref Google Scholar, 17.Kunutsor S.K. Seidu S. Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.Eur Heart J. 2017; 38: 1608-161210.1093/eurheartj/ehx107Crossref PubMed Scopus (44) Google Scholar Therefore, the net benefit of statins may be higher in high‐risk VTE patients, especially those with cardiovascular risk, and potentially be useful in secondary prevention of VTE. However, whether statins can be an attractive anticoagulant replacement therapy during long‐term treatment of VTE needs confirmation via randomized trials. Today, there is little evidence on statin dosage and type. Rosuvastatin 20 mg daily is “royal” in RCT trials,3.Glynn R.J. Danielson E. Fonseca F.A. et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N Engl J Med. 2009; 360: 1851-186110.1056/NEJMoa0900241Crossref PubMed Scopus (605) Google Scholar, 13.Ramberg C. Hindberg K. Biedermann J.S. et al.Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: a randomized controlled trial.J Thromb Haemost. 2022; 20: 877-88710.1111/jth.15626Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar while in most cohort studies, statin type ranges from simvastatin to lovastatin without comparisons among statin types and dosages.4.Braekkan S.K. Caram‐Deelder C. Siegerink B. et al.Statin use and risk of recurrent venous thrombosis: results from the MEGA follow‐up study.Res Pract Thromb Haemost. 2017; 1: 112-11910.1002/rth2.12003Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar, 5.Smith N.L. Harrington L.B. Blondon M. et al.The association of statin therapy with the risk of recurrent venous thrombosis.J Thromb Haemost. 2016; 14: 1384-139210.1111/jth.13334Crossref PubMed Scopus (25) Google Scholar In another study, Siniscalchi et al.7.Siniscalchi C. Surinach J.M. Visona A. et al.Different types of statins and all‐cause mortality during anticoagulation for venous thromboembolism: validation study from RIETE Registry.TH Open. 2020; 4: e236-e24410.1055/s‐0040‐1716734Crossref Google Scholar compared different types of statins and all‐cause mortality of patients with VTE during anticoagulation. Compared to non‐statin users, patients on simvastatin or other statins had a lower mortality rate, but there was no significant difference in mortality among among patients on atorvastatin or rosuvastatin. Recently, Siniscalchi et al.18.Siniscalchi C. Muriel A. Surinach J.M. et al.Statin use and 30‐day mortality in patients with acute symptomatic pulmonary embolism.J Thromb Haemost. 2022; 10.1111/jth.15753Abstract Full Text Full Text PDF Scopus (1) Google Scholar assessed the strength of associations across the strata of intensities of statin therapy on mortality. Considering the diversity of statins, it may be more beneficial to compare statin intensities. It should be noted that although low and medium doses of statins can decrease the prevalence of fatal PE, there is no significant difference at high doses. Although the authors do not elaborate on this phenomenon in detail, safety of statins requires our attention. In summary, the study by Siniscalchi et al. adds to the growing body of evidence that statins have a protective effect against short‐term mortality in acute symptomatic PE. The effect appears to be of clinical relevance and supported by statin intensities. Large prospective randomized trials of statins, notably statin type and intensity, are warranted to confirm the potential benefits in fatal PE. The authors declare no conflicts of interest. All authors conceived and designed the article, performed analysis and interpretation of the data, revised the manuscript critically for important intellectual content, and gave final approval of the manuscript submitted. Z.C.J acknowledges research support from CAMS Innovation Fund for Medical Sciences (CIFMS), funded by the Chinese Academy of Medical Sciences (2021‐1‐I2M‐018). Rong Jiang acknowledges research support from National Natural Science Foundation of China (81700045).National Natural Science Foundation of China81700045CAMS Innovation Fund for Medical Sciences2021‐1‐I2M‐018